[Effect of 1,25-dihydroxycholecalciferol in renal osteopathy].
9 patients with advanced renal failure and renal osteodystrophy documented by iliac crest biopsy were treated with 1,25-dihydroxycholecalciferol (average dose 0.53 micrograms per day) for 6 months. Under 1,25-DHCC there was a statistically significant increase in serum calcium and decrease in serum alkaline phosphatase and immune parathyroid hormone. Histomorphometric evaluation of posttreatment bone biopsies showed reduction of osteoclastic resorption and endosteal fibrosis. Osteoid volume decreased in most cases. In 3 patients with predominant fibroosteoclasia, bone turnover practically normalized. Bone mineral content of the radius (photoabsorptiometry) did not change with treatment. Transient hypercalcemia occurred in 5 patients and was easily corrected by adjustment of 1,25-DHCC dosage.
D000469:Alkaline Phosphatase / Q000378:metabolism; D000536:Aluminum Hydroxide / Q000627:therapeutic use; D001847:Bone Diseases / Q000188:drug therapy* / Q000209:etiology; D001862:Bone Resorption / Q000187:drug effects; D002118:Calcium / Q000097:blood; D004100:Dihydroxycholecalciferols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood
D004100:Dihydroxycholecalciferols; D006887:Hydroxycholecalciferols; D010281:Parathyroid Hormone; D000536:Aluminum Hydroxide; D000469:Alkaline Phosphatase; D002118:Calcium
Wirkung von 1,25-Dihydroxycholecalciferal bei renaler Osteopathie.